Abstract: Drug repositioning is an important component of therapeutic stratification in the precision medicine paradigm. Molecular profiling and more sophisticated analysis of longitudinal clinical data are refining definitions of human diseases, creating needs and opportunities to re-target or reposition approved drugs for alternative indications. Drug repositioning studies have demonstrated success in complex diseases requiring improved therapeutic interventions as well as orphan diseases without any known treatments. An increasing collection of available computational and experimental methods that leverage molecular and clinical data enable diverse drug repositioning strategies. Integration of translational bioinformatics resources, statistical methods, chemoinformatics tools and experimental techniques (including medicinal chemistry techniques) can enable the rapid application of drug repositioning on an increasingly broad scale. Efficient tools are now available for systematic drug-repositioning methods using large repositories of compounds with biological activities. Medicinal chemists along with other translational researchers can play a key role in various aspects of drug repositioning. In this review article, we briefly summarize the history of drug repositioning, explain concepts behind drug repositioning methods, discuss recent computational and experimental advances and highlight available open access resources for effective drug repositioning investigations. We also discuss recent approaches in utilizing electronic health record for outcome assessment of drug repositioning and future avenues of drug repositioning in the light of targeting disease comorbidities, underserved patient communities, individualized medicine and socioeconomic impact.
DRUG REPOSITIONING
Drug repositioning was defined as systematic or targeted evaluation of pharmaceutical compound libraries or compound to identify new indications for diseases other than the primary diseases for which the drug was originally designed [1] [2] [3] [4] . It is a rapidly evolving area in the field of drug discovery at the interface of medicinal chemistry, chemoinformatics, biomedical informatics and pharmacology. Drug repositioning can play a key role in therapeutic stratification for patients with rare, complex or chronic diseases with less effective or no marketed treatment options available [5] [6] [7] [8] .
Compounds at all stage of development in drug development cycle, clinical trials or experimental medicine projects can be used as candidates for drug repositioning followed by toxicity studies to identify new indications. Clinical knowledge from secondary or off-label use and even side effects of approved pharmaceutical compounds can also be used in drug repurposing methods [9, 10] . Longitudinal disease diagnosis and prescription data from electronic health records (EHR) can be abstracted and analyzed to understand the *Address correspondence to this author at the Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Tel: 212-659-8656; E-mail: joel.dudley@mssm.edu effectiveness and outcome of drug repositioning [10, 11] based on Pharmacovigilance 2.0 guidelines [12, 13] .
Attempts have been made by ourselves [2] and Murterial et al. [14] to conceptually classify and define various modalities and approaches to drug repositioning. We have provided an overview of definitions for drug repositioning and other related methods that utilize re-use or repositioning of pharmaceutical compounds ( Table 1) . Concepts of drug reformulation, drug combination, altered dosing, altered mode of delivery, line extension and therapeutic switching are some related concepts, but do not qualify as drug repositioning examples. Although, such compound reuse and reformulation approaches can play an important role in drug repurposing studies, in terms of getting a repurposed compound or formulations to the market. While different terms like drug repositioning, drug repurposing, drug profiling have been used to define similar approaches of using pharmaceutical compounds for new indications, we will be using the term drug repositioning in this review.
BRIEF HISTORY OF DRUG REPOSITIONING
Drug repositioning has been successful in different classes of diseases defined across the International Statistical Classification of Diseases and Related Health Problems (ICD-9; http://www.who.int/classifications/icd/en/) disease classification system [1, 2, [7] [8] [9] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . The concept of using approved or regulated drugs for new indications can be traced back to the 1950s [29, 30] . The use of reticulose (lipoprotein nucleic acid complex) as a drug for postradiation effects is among the earliest examples of drug repositioning. Later examples include evaluating anti-malarial drugs in systemic lupus erythematosus, rheumatoid arthritis, and connective tissue diseases [31] [32] [33] . More recent commercially successful examples of drug repurposing include the use of thalidomide as an anticancer agent and the use of duloxetine as an experimental drug for urinary tract infection [34] [35] [36] [37] [38] [39] [40] . The advent of genomics technologies and computational approaches has led to the development of novel approaches for drug repositioning. Recent drug repositioning discoveries enabled by computational and genomic technologies includes the discovery of tricyclic antidepressants as inhibitors of small cell lung cancer through a genesignature based approach [19] , using the PharmGKB database for data-driven repositioning for breast cancer [41] and use of anthelmintics for the treatment of colon cancer [42] .
COMPUTATIONAL AND EXPERIMENTAL METH-ODS FOR DRUG REPOSITIONING
Drug repositioning methods can be focus around a target (target-based repositioning methods) [43] [44] [45] , disease (disease-based drug repositioning) [17, 46] , expression datasets (signature-based drug repositioning) [17, 19] , repositioning investigations aimed broadly at identifying global relationships among drugs, targets, and diseases to identify novel drug repurposing opportunities in a hypothesis-free approach(systematic drug repositioning) [17] or network-scale data (network-based drug repositioning) [2, 16, 17] . Flowcharts to compare target-driven drug discovery pipeline and computational drug repositioning methods are shown in (Fig.  1) . Computational and experimental approaches can be leveraged to implement various modalities of drug repositioning. Both computational screening and experimental screening methods can be utilized for repurposing investigations. In recent years, drug repositioning investigations are performed as hybrid approach where results from computational analyses were validated by experimental assays, followed by clinical trials designed to understand therapeutic efficacy of the new indication [16, 43, 44, [47] [48] [49] [50] .
Both computational and experimental approaches are important elements of drug repurposing strategies. Computational methods play a pivotal role in accelerating drug repurposing studies. Computational methods and predictive modeling can be used for integration of large and diverse data sets from chemical, genomic, and clinical investigations required for drug repositioning studies [51] [52] [53] [54] [55] [56] [57] [58] . Summaries of recent computational advances in drug repositioning provided in (Table 2) . A group of semi-throughput and highthroughput experimental approaches are being used for systematic drug repositioning. These include data generating from target-based screens, molecular profiling screens (e.g., gene expression profiling), and phenotypic screens [18, 48, [59] [60] [61] . A summary of recent developments in the experimental approaches for drug repositioning summarized in (Table 3) .
A METHODOLOGICAL OVERVIEW OF COMPU-TATIONAL DRUG REPOSITIONING
Drug repositioning investigations can be performed as workflow based, automated bioinformatics approaches and also as a tailored analysis around the pathophysiology of the disease using information about target molecules or target networks and associated expression data. Various approaches require an array of carefully designed multi-step analyses for candidate compound identification; compound prioritization coupled with well-designed validation experiments. Irrespective of the variations in the drug repositioning study design, drug repositioning study can be broadly classified into a three-step process: primary analyses, secondary analyses and tertiary analyses. Typically a primary analysis can be initiated using data from expression signatures, target biology, protein-protein or protein-small molecule network datasets (co-expression or Bayesian) and generate a list of ranked compounds for further evaluation. Secondary analysis refers to a collection of analyses approaches to filter or prioritize compounds for validation. Finally, tertiary analyses aim to validate the compounds using experimental approaches, pre-clinical models and assess outcomes of the drug repositioning using longitudinal mining of EHR data. Here we are discussing methodological overview using an example of the signature-based drug repositioning method.
PRIMARY

ANALYSES-IDENTIFICATION OF PHARMACEUTICAL COMPOUNDS FOR DRUG-REPOSITIONING
Signature-based drug repositioning uses a compendium of transcriptomic signatures derived from RNA expression levels of various cell-lines with and without perturbation of a 
Computational Methods Examples
Drug combination prediction Target inhibion networks were designed to block cancer survival pathways [111] EHR based drug repositioning Data from EHRs were utilized for off-label drug uses in clinical setting [10] and drug repositioning trials [112] Fragment-based drug repositioning Nonsteroidal anti-inflammatory drug (NSAIDs) Celecoxib and its template compounds were indicated as STAT3 inhibitors by integrating fragment based screening and drug repositioning. [113, 114] Genome-based drug repositioning Data from GWAS, SiRNA screening and genome-scale network were used to prioritize targets for drug repositioning [59, [115] [116] [117] Network-based drug repositioning Knowledge-based, graph-based or topological analyses of networks of proteins, genes or co-expression networks were used to evaluate candidate small molecules for repositioning. [1, 16, 48-50, 55, 118-127] Neural network-based drug repositioning Neural network based prediction of chemogenomic drug sensitivity [128] Off-targeting data driven repositioning Antiretroviral drug Nelfinavir was repositioned as anticancer molecule based on off-targeting of the molecule agains EGF receptor and cytosolic protein kinase B [129] Pathway based repositioning Drug targets were identified across multiple respiratory viruses based on human host gene expression analysis [130] Protein-protein interaction driven prioritization Protein-network based elucidation of pathophysiological mechanisms of Usher syndrome [131] Protein-small molecule interactions De-novo target discovery, network and chemogenomic analyses [48, 54, 55] Structure based drug repositioning Protein structure data was utilized for chemogenomic screening, analyzing drug-target network for polypharmacology indications and drug scaffold refinement [123, 132, 133] Systematic drug repositioning Tricyclic antidepressants were repositioned as inhibitors of small cell lung cancer and other neuroendocrine tumors [19] Text-mining driven drug repositioning Multiple studies have used text-mining approaches for inferring common properties of drugs or target proteins [134, 135] Topic modeling FDA drug labels were analyzed using a probabilistic topic model to find drug pairs for common indications [135] Table 3. Experimental approaches in drug repositioning and associated therapeutic areas.
Experimental Approaches Comments Therapeutic Area
Chemical genomics Application of chemical probes, small molecule libraries or perturbagens to probe cell-lines for initial assessment followed by selective testing in animal models
Infectious diseases (malaria) [136, 137] Chemical systems biology Combining structural bioinformatics methods (ligand screening, docking), pharmacoinformatics followed by in vitro assays and kinetic assays
Infectious diseases (tuberculosis) [138] Clinical side-effects A database of disease-side effect associations was constructed and integrated with canonical drug repositioning methods Multiple therapeutic areas [21] Genome-wide association studies (GWAS) GWAS based candidate variant to gene(s) prioritization used for targetdriven drug repositioning
Subset of clinical traits and diseases from GWAS catalog [116] Medical genetics Genetic or genomic evidence based candidate gene(s) prioritization for target-driven drug repositioning
Cancer, Genetic diseases from OMIM and GWAS [117, 139, 140] MicroRNA (miRNA) expression Compiling expression data of miRNAs and targeting miRNAs could improve repositioning
Cancer, other complex and chronic diseases [141] ( Table 3) contd….
Network medicine Knowledge-based, graph-based or topological analyses of network of proteins and genes were used to evaluate candidate small molecules for repositioning.
Multiple therapeutic domains [1, 16, 48-50, 55, 118-127] Serological marker Neo-epitopes -a class of serological biomarkers were used for drug repositioning Multiple therapeutic areas [142] Small interference RNA (SiRNA) screening High-throughput, transient and stable RNA interference (RNAi) screening was used to prioritize target for drug repositioning Host-pathogen interactions; infectious diseases [59] Transcriptomic response Drug induced transcriptional response were used for prioritizing repositioning candidates
Cancer, other complex and chronic diseases [56, 143, 144] library of small molecules. Publicly available resources like Connectivity Map (cmap http://www.broadinstitute.org/ cmap/) [62] [63] [64] and LINCS (http://www.lincsproject.org/) have generated thousands of drug induced transcriptional profiles representing a diverse range of FDA approved drugs, experimental compounds and research probes. One approach begins with investigators defining a biological state of interest, (which may reflect differential gene expression from an affected tissue in a disease of interest) in the form of "upregulated" and "downregulated" gene identifiers. These identifiers can be used as input to tools like cmap [65] [66] [67] [68] , Genomics of Drug Sensitivity in Cancer (GDSC) [69] or Cancer Cell Line Encyclopedia (CCLE) [70] . Many algorithms are available to process lists with direction of expressions [7, 27, 67, 71] , but in general, algorithms score the input query against the available drug induced signatures, to identify compounds that concordantly modulate the query signature in a direction "towards" or "away" from the query state. A number of statistical approaches can be used to calculate this "connectivity score", assign statistical significance and control the false discovery rate. These primary analyses produce a ranked list of candidate compounds that may potentially modulate (as within the scope of the assayed cell lines or quantity of replicates) a biological state of interest. Depending on the appropriate validation experiments, for a biological state of interest, there are often many more candidate compounds than would be feasible to escalate to experimental validation, and hence, systematic methods are required to prioritize top ranking compounds for further analyses.
Targeted drug repositioning using a protein structure or putative set of protein targets and search a compound library for pharmaceutical molecules, ligand databases or pharmacophore libraries that can activate, inhibit downstream functional effects, protein-protein interactions or enzymatic reactions. This approach, similar to high-throughput screening using medicinal chemistry platforms provides a set of ligands and statistical metrics to define the binding, activity or functional indications. Detailed account of the methodology to derive ligands sets for target based repositioning were described elsewhere [20, 72] . Irrespective of the study design; primary analyses provide a list of compounds with a ranking and a statistical metric to indicate the significance.
SECONDARY ANALYSES-PRIORITIZATION OF PHARMACEUTICAL COMPOUNDS FOR DRUG-REPOSITIONING
Once list of compounds are identified using systematic repositioning or target-based repositioning analyses, multiple filtering approaches can be used to prioritize candidate compounds for experimental validation. These approaches are similar to a chemical screening method in medicinal chemistry. Computational methods are available to integrate orthogonal data types to support the interpretation of the list of compounds generated using primary analyses. Compounds can also be prioritized using patent life, toxicity, mechanism of action, routes of delivery and other biological, physiological, chemical or disease specific features. Although these compounds will have certain similarities in their transcriptional or other molecular signature (as implied by a robust relationship to the query state or ligand specificities), the biological interpretation of this is not always clear. To help identify the shared biological underpinnings of the given set of candidate compounds, a series of secondary analyses on this list of compounds can be performed, using a range of biological, pathway and other ontology or rich-annotation databases driven enrichment analyses. Using an enrichment analysis tests [73] [74] [75] , enriched terms associated with the list of candidate compounds can be identified. Careful evaluation of enrichment analyses can help to identify of possible mechanisms of action of relevance to the disease, and can potentially be used as the basis for a further compound queries and prioritization. For example inferences like compound list is enriched for G-protein coupled receptor (GPCR) agonists; compounds were enriched for anticholinergic molecules or targets are encoded with signaling domains as PDZ etc. can be obtained from this step. Integrating this information with pathophysiology of the chronic, common or rare disease also requires extensive biocuration [76] . In summary, secondary analyses steps can help identify the biological themes, which may underlie the shared drug signature of a set of candidate compounds, which can help prioritize compounds for further validation.
TERTIARY ANALYSES -VALIDATION OF PHAR-MACEUTICAL COMPOUNDS FOR NEW INDICA-TION AND PHARMACOVIGILANCE USING EHR
Prioritized compounds from secondary analyses of drug repositioning investigations need rigorous experimental and clinical evaluation before the release as new indications. These steps include validation in animal models, dose evaluations and clinical trials to assess efficacy of new indications. EHR based pharamacovigilance can be also performed as part of tertiary analyses. Tertiary analyses in drug repositioning can be divided as a bimodal approach:
a) Experimental Validation and Clinical Trials for New Indications
Based on biomolecular, network driven, or chemogenomic insights gained from secondary analyses, a subset of compounds can be now prioritized for experimental evaluation. The quantity of compounds to be experimentally validated will vary depending on the cost and complexity of the relevant preclinical models. A typical experimental evaluation may involve cell-line based targeted assays; this will be followed by a closely monitored experimental evaluation in disease-relevant animal. This step would include evaluating the compound for both known and unknown side effects, toxicity, pharmacokinetics and bioavailability testing. Dosing of the compound and its impact on the clinical manifestation of the disease would be assessed at this stage. This preclinical development step combined with data from previous experiments and literature will be helpful for investigators to plan clinical trials for the compound and its new indications. An illustrative summary of the three steps involved in systematic drug repositioning using expression signature is provided in (Fig. 2). 
b) Outcome Analysis of Drug Repositioning Using Longitudinal EHR Mining
An EHR system captures several clinical variables including vital signs, biomarkers and clinical chemistry data associated with the patient during outpatient visit, inpatient stay and based on self-reported patient surveys. Recently, Jung et al. [10] showed that longitudinal data from EHR can be analyzed for off-label use and additional evidences to support drug repositioning studies. EHRs can be used to evaluate the outcome of drug repositioning investigations. Pharmacovigilance using EHR can be performed as an alternate or complementary validation step to understand the efficacy of drug repositioning investigations. Implementations of EHR based pharmacovigilance workflows are currently limited. We envisage that nation-wide EHR implementation and meaningful use certifications at hospitals in the US to receive the incentive payment from Centers for Medicare and Medicaid Services (CMS) would fuel the wide-adoption of such approaches in the near future (http://www.cms.gov/ Regulations-and-Guidance/Legislation/HER Incentive Programs/Meaningful_Use.html). Efforts are also needed from EHR vendors and application designers to develop data elements to capture diverse clinical phenotypes related to drug repositioning and therapeutic stratifications.
COMPUTATIONAL DRUG REPOSITIONING USING OPEN ACCESS TOOLS
An array of biomedical informatics databases, webservers, software modules and chemoinformatics toolkits are available for computational drug repositioning. Databases of drug-induced transcriptional signatures, as well as higherlevel drug annotations, such as drug-drug interactions, side effects, small molecule libraries, bioactivities, and compound-target binding kinetics datasets are now available. Databases also provide access to various meta-data including druggability of targets, compounds with regulatory agency approval status, collection of pre-clinical compounds, new molecular entities (NMEs) and experimental biopharmaceuticals repositories. Tools are also available for matching a given disease signature to a database of transcriptomic signatures and computing various properties. A subset of openaccess databases, webservers and software toolkits for drug repositioning listed in (Table 4) .
DRUG REPOSITIONING AND RELATED METHODS FOR THERAPEUTIC STRATIFICATION
Therapeutic stratification is an emerging concept of providing precise, personalized and data-driven therapeutic recommendations based on biological insights gained from riskprediction models, molecular profiling of the patient using multi-omic experiments and pharmacogenomic information [77] . Integrating risk-prediction models and molecular profiling data with drug repositioning approaches could help patients to access better treatment in a shorter amount of time. Tumor grade-based treatment to treat cancer patients [78] , recommending medications to lower the risk of adverse cardiovascular outcomes based on risk models [79] and genetic variants from personalized genome scans [80] or using multi-omic (genome, transcriptome or metabolomics) information to capture molecular state of the patient and use it for therapeutic recommendations are some of the recent examples of therapeutic stratifications. [81] [82] [83] . With the advent of low-cost, high precision molecular profiling techniques, molecular profiling can be performed at the hospital setting and could aid in therapeutic stratification of patients with complex or rare clinical manifestations.
NEW AVENUES FOR THE APPLICATION OF DRUG REPOSITIONING
Targeting disease comorbidity subgroups, matching drugs to specific patients for individualized medicine, and identifying off-label use of FDA approved drugs for orphan diseases represent areas of high potential for the use of drug repositioning.
TARGETING DISEASE COMORBIDITIES
Disease comorbidities are a key component in defining individualized clinical phenomic profile of patients [84] . Treatment strategies that consider a primary disease and its comorbidities may have a better outcome compared to treating the condition as a singular clinical manifestation. Incorporating the existing knowledge of population specific, age and gender matched disease comorbidities in drug repurposing pipelines may also help to identify better drug targets and new indications for existing disease based on shared pathophysiology modules of disease [85] [86] [87] [88] [89] .
DRUG REPOSITIONING FOR ORPHAN DISEASES
Rare diseases (diseases that affect one in 1,500 people in the United States) are now being cataloged in public access Orphan designated products with at least one approval for common disease (n=166); Orphandesignated products with at least one marketing approval for a rare disease indication (n=179); Orphan-designated products with marketing approvals for both common and rare disease indication resources such as the Orphanet (See: http://www.orpha.net/) and Genetic and Rare Diseases Information Center (GARD) http://www.rarediseases.info.nih.gov/gard. These numbers are expected to grow as more and more families with rare disorders can be profiled using next-generation sequencing for identification of underlying genetic variation. Information about disease associated variants and genes from familial or small-cohort sequencing studies will be helpful in designing target-driven drug repurposing for rare diseases [90] . Drug repositioning investigations targeting orphan diseases have significant potential in providing faster therapeutic options for patients [9, 91] .
DRUG REPOSITIONING IN INDIVIDUALIZED MEDICINE
Drug repositioning methods are poised to play a key role in individualized medicine, given the growing importance of preventive and precise treatment strategies tailored to individuals. Computational drug repositioning strategies can be implemented using personalized exome, genome, transcriptome or metabolome analyses for faster insights into the proteins or disease networks that can target and small molecules that could perturb them for therapeutic stratification [82] . Integrating drug repositioning approaches with existing genetic variant or transcriptome analyses and rapid medicinal chemistry evaluations in the clinical setting could drastically reduce the time for translation of therapies from bench to bedside [53, 82] . Initiatives like Dialogue on Reverse Engineering Assessment and Methods (DREAM) (http:// www.the-dream-project.org/challenges/nci-dream-drugsensitivity-prediction-challenge) also push research and academic communities to design innovative solutions to address challenges in the field of drug sensitivity prediction. The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov /) and Pan-Cancer Analysis Projects [92] also provide a wide array of cancer profiles that can potentially be leveraged for personalized therapeutic stratification.
SOCIO-ECONOMIC IMPACT OF DRUG REPOSI-TIONING
Developing a new drug from the discovery phase to market requires significant investments in time (~15 years) and resources (USD $800-$1 billion) [2, [93] [94] [95] . Chemical screening [96] , lead identification [97] , biological experimentation by in-vitro and in-vivo validation studies and extensive multi-center clinical trials [18, [98] [99] [100] [101] [102] [103] . Lead molecules are also rigorously assayed to define pharmacological effects, bioavailability, the optimal dosing and formulation, and potential toxicity assessments. Irrespective of the dynamics in pharmaceutical, pre-clinical and drug-development budgets, drugs are often burdened with known and unknown side effects that lead to the recall of the drug (See: http://www.fda.gov/Safety/MedWatch/ and http://www.fda. gov/drugs/guidancecomplianceregulatoryinformation/surveil lance/adversedrugeffects/ucm070093.htm). These aspects influence the product development and revenue cycles of pharma companies, which in turn affect the pricing of the drug. United States patent rules can also limit the return of the investment (ROI) for pharmaceutical companies due 20-year patent rule with an additional five years of patent exclusivity based on the Hatch-Waxman act (Public Law 98-417; http://www.gpo.gov/fdsys/pkg/STATUTE-98/pdf/ STATUTE-98-Pg1585.pdf). In such a scenario patients, care providers or payers have to share the high cost of medications [104] [105] [106] . By contrast, drug repositioning investigations can bring new therapies to market in approximately half the budget and time required by traditional drug development cycle [107] . This is possible due to the availability of pre-existing data on efficacy, toxicity and dosing along with prior biological knowledge of the compounds. Compared to traditional drug discovery pipelines that screen thousands of molecules with known and unknown toxicity profiles, drug repositioning focuses on experimentally verified, FDA approved molecules or pre-clinical compounds that are either an already successful drug or drugs that are retracted due to adverse reactions when used against the primary indication. This targeted re-use and recycling approach helps in reducing the cost of drug discovery pipelines and thus could help to reduce the cost to the patient population, further enabling the patients to access better therapeutics with shorter times for translation of therapies from clinical research to therapeutic interventions [26, 108] .
Relicensing a compound for new indications may also help the pharmaceutical companies and experimental investigators expand the patent exclusivity by altering the mode of delivery, dosing or via combination therapy. Due to off-label use, repositioning an off-patent drug in the United States might not be a financially lucrative option for pharma companies, it could help inform policy efforts in other countries to consider drug repositioning strategies as part of drug discovery lifecycle. For example repositioning a cheap and widely available drug for malaria or tuberculosis for a new indication with costly therapeutic options can make the treatment affordable to larger, underserved patient communities. Patents, policies and cost estimate around drug repositioning are evolving in different countries. Unified guidelines to protect drug repositioning based indications and provide affordable therapeutic options based on existing indications in faster turnaround time could ultimately improve therapeutic outcomes [106, 109, 110] .
TOWARDS A GLOBAL CATALOG OF DRUG REPO-SITIONING
More than 300 drug-repositioning examples were reported in the literature and a catalog is currently being developed (Manuscript in preparation). A striking observation from the drug repositioning catalog is the importance of different axes of similarity between the disease states and drug groups that are implied by specific drug repositions. For example intra-disease category repositioning (primary and secondary indications are in the same sub or primary category of ICD-9 coding system), inter-disease category repositioning (primary and secondary indications are in different primary category of ICD-9 coding system), comorbid conditions and underlying pathophysiological modules could also drive successful repositioning. A subset of cancer drugs repurposed to another class of diseases in the ICD-9 classification is provided in (Fig. 3) . Analyzing a large number of successful drug repositioning examples would help to design predictive models and gain novel insights to global properties of drug repositioning (Manuscript in preparation). Fig. (3) . Drug repositioning of cancer drugs. Nodes are different disease categories based on ICD-9 definitions. Edge labels indicates names of drugs primarily designed to treat a cancer and repurposed for a secondary indication including other types of cancers.
FUTURE OUTLOOK
Agents that have failed clinical trials due to lack of efficacy or minor adverse profiles can also be used as candidates for drug repositioning as part of a systematic drug repositioning pipeline followed by toxicity studies of the new indications. Drug repositioning offers a cost-effective, accelerated and effective strategy for pharmaceutical companies and discovery driven treatment options for patients. Focused clinical trials may be required to re-validate the use of repurposed indications. Ancillary techniques of repositioning including reformulation strategies (altered dosage, drug combinations, mode of delivery) can help to identify better therapeutic interventions for complex and orphan diseases alike. Repositioning investigations can also reveal serendipitous examples where a prior clinical, comorbidities, shared pathway or other biological evidences does not exist. Such offtarget or polypharmacology driven results can be further perturbed using controlled experiments to understand shared disease pathways. The future outlook of drug repositioning is promising for patient communities, translational researchers and the pharmaceutical industry. Patient communities will greatly benefit from drug repositioning as it provides accelerated treatment strategies with limited side effects in a short period compared to the traditional drug development life cycle. Understanding clinical representations and their molecular phenotype is key for translational research and enabling precision medicine. Tracking the mechanism of actions for new indications could also help in understanding the molecular basis of genetic, complex, chronic or rare diseases. Pharmaceutical companies could leverage their large repertoires of public and private compound libraries in search of molecules that can provide better secondary indications and primary indications for rare diseases.
CONCLUSION
Increasing growth of the global population along with a growing global disease burden, emergence of new infectious diseases, high rates of drug resistance in cancers and chronic diseases and multi-drug resistant pathological strains call for the immediate requirement of effective therapies to improve global health. Drug repositioning solves an important gap in public health setting by providing alternate therapeutic compounds for complex, chronic or orphan diseases using molecular information derived from a single patient; family members with rare clinical manifestation or case-control cohorts. Several successful use cases of drug repositioning were reported across different therapeutic domains. Designing semi-automated workflows that can handle multi-omic analyses coupled with software modules for drug repositioning and validation using medicinal chemistry experiments would rapidly improve therapeutic stratifications for a wide array of diseases.
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